Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells



Status:Completed
Conditions:Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 60
Updated:10/20/2018
Start Date:September 2007
End Date:March 15, 2011

Use our guide to learn which trials are right for you!

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not
completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces
tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the
expression of SOCS3 in DCs.


Inclusion Criteria:

- Confirmed diagnosis of MS

- Age 18-60 years, inclusive

- Expanded disability status of 0-6.5

- Give written informed consent prior to any testing under this protocol
We found this trial at
1
site
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials